Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients by Strippoli, Giovanni F.M. et al.
Cochrane Database of Systematic Reviews
Antimicrobial agents for preventing peritonitis in peritoneal
dialysis patients (Review)
Strippoli GFM, Tong A, Johnson DW, Schena FP, Craig JC
Strippoli GFM, Tong A, Johnson DW, Schena FP, Craig JC.
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.
Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004679.
DOI: 10.1002/14651858.CD004679.pub2.
www.cochranelibrary.com
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
7DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Oral antibiotics versus none, Outcome 1 Mortality (all cause). . . . . . . . . . 26
Analysis 1.2. Comparison 1 Oral antibiotics versus none, Outcome 2 Mortality due to peritonitis. . . . . . . . 27
Analysis 1.3. Comparison 1 Oral antibiotics versus none, Outcome 3 Peritonitis (number of patients with one or more
episodes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Analysis 1.4. Comparison 1 Oral antibiotics versus none, Outcome 4 Peritonitis rate (episodes/patient-months on PD). 28
Analysis 1.5. Comparison 1 Oral antibiotics versus none, Outcome 5 Exit-site/tunnel infection (number of patients with
one or more episodes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Analysis 1.6. Comparison 1 Oral antibiotics versus none, Outcome 6 Exit-site/tunnel infection rate (episodes/total patient-
months on PD). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Analysis 1.7. Comparison 1 Oral antibiotics versus none, Outcome 7 Catheter removal or replacement. . . . . . 30
Analysis 1.8. Comparison 1 Oral antibiotics versus none, Outcome 8 Pruritus (generalised). . . . . . . . . . 30
Analysis 1.9. Comparison 1 Oral antibiotics versus none, Outcome 9 Diarrhoea. . . . . . . . . . . . . . 31
Analysis 1.10. Comparison 1 Oral antibiotics versus none, Outcome 10 Nausea. . . . . . . . . . . . . . 31
Analysis 1.11. Comparison 1 Oral antibiotics versus none, Outcome 11 Allergy. . . . . . . . . . . . . . 32
Analysis 1.12. Comparison 1 Oral antibiotics versus none, Outcome 12 Nasal irritation. . . . . . . . . . . 32
Analysis 1.13. Comparison 1 Oral antibiotics versus none, Outcome 13 Fungal peritonitis (number of patients with one or
more episodes). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Analysis 1.14. Comparison 1 Oral antibiotics versus none, Outcome 14 Fungal peritonitis rate (episodes/patient-months
on PD). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Analysis 2.1. Comparison 2 Nasal antibiotics versus none, Outcome 1 Mortality (all cause). . . . . . . . . . 34
Analysis 2.2. Comparison 2 Nasal antibiotics versus none, Outcome 2 Peritonitis (number of patients with peritonitis). 34
Analysis 2.3. Comparison 2 Nasal antibiotics versus none, Outcome 3 Peritonitis rate (episodes/patient-month versus total
patient-months). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Analysis 2.4. Comparison 2 Nasal antibiotics versus none, Outcome 4 Exit site and tunnel infection (number of patients
with exit site and tunnel infection). . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Analysis 2.5. Comparison 2 Nasal antibiotics versus none, Outcome 5 Exit site and tunnel infection rate (episodes/patient-
month versus total patient-months). . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Analysis 2.6. Comparison 2 Nasal antibiotics versus none, Outcome 6 Catheter removal or replacement. . . . . . 37
Analysis 2.7. Comparison 2 Nasal antibiotics versus none, Outcome 7 Nasal irritation/rhinitis. . . . . . . . . 37
Analysis 2.8. Comparison 2 Nasal antibiotics versus none, Outcome 8 Headache. . . . . . . . . . . . . . 38
Analysis 2.9. Comparison 2 Nasal antibiotics versus none, Outcome 9 Diarrhoea. . . . . . . . . . . . . 38
Analysis 2.10. Comparison 2 Nasal antibiotics versus none, Outcome 10 Nausea. . . . . . . . . . . . . . 39
Analysis 2.11. Comparison 2 Nasal antibiotics versus none, Outcome 11 Vomiting. . . . . . . . . . . . . 39
Analysis 2.12. Comparison 2 Nasal antibiotics versus none, Outcome 12 Pruritus. . . . . . . . . . . . . 40
Analysis 2.13. Comparison 2 Nasal antibiotics versus none, Outcome 13 Peritonitis. . . . . . . . . . . . 40
Analysis 2.14. Comparison 2 Nasal antibiotics versus none, Outcome 14 Peritonitis rate. . . . . . . . . . . 41
Analysis 2.15. Comparison 2 Nasal antibiotics versus none, Outcome 15 Exit-site/tunnel infection. . . . . . . 41
iAntimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.16. Comparison 2 Nasal antibiotics versus none, Outcome 16 Exit-site/tunnel infection rate. . . . . . 42
Analysis 3.1. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials), Outcome 1
Peritonitis (number of patients with peritonitis). . . . . . . . . . . . . . . . . . . . . . . 42
Analysis 3.2. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials), Outcome 2
Exit site and tunnel infection (number of patients with exit site and tunnel infection). . . . . . . . . . 43
Analysis 3.3. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials), Outcome 3
Catheter removal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Analysis 3.4. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials), Outcome 4
Death. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 5.1. Comparison 5 Topical disinfectants versus none, Outcome 1 Mortality (all cause). . . . . . . . . 44
Analysis 5.2. Comparison 5 Topical disinfectants versus none, Outcome 2 Exit site and tunnel infection (number of
patients with exit site and tunnel infection). . . . . . . . . . . . . . . . . . . . . . . . 45
Analysis 5.3. Comparison 5 Topical disinfectants versus none, Outcome 3 Peritonitis (number of patients with
peritonitis). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Analysis 5.4. Comparison 5 Topical disinfectants versus none, Outcome 4 Catheter removal or replacement. . . . 46
Analysis 5.5. Comparison 5 Topical disinfectants versus none, Outcome 5 Technique failure. . . . . . . . . . 47
Analysis 5.6. Comparison 5 Topical disinfectants versus none, Outcome 6 Pruritus (local). . . . . . . . . . 47
Analysis 6.1. Comparison 6 Germicidal chamber versus none, Outcome 1 Peritonitis rate (episodes/patient-month versus
total patient-months). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Analysis 6.2. Comparison 6 Germicidal chamber versus none, Outcome 2 Mortality (all cause). . . . . . . . . 48
Analysis 7.1. Comparison 7 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 1 Peritonitis rate
(episodes/patient-month versus total patient-months). . . . . . . . . . . . . . . . . . . . . 49
Analysis 7.2. Comparison 7 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 2 Exit site and tunnel
infection rate (episodes/patient-month versus total patient-months). . . . . . . . . . . . . . . . 49
Analysis 8.1. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 1 Mortality (all cause). . . . . 50
Analysis 8.2. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 2 Exit site and tunnel infection (number
of patients with exit site and tunnel infection). . . . . . . . . . . . . . . . . . . . . . . 51
Analysis 8.3. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 3 Peritonitis (number of patients with
peritonitis). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Analysis 8.4. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 4 Peritonitis rate (episodes/patient-
month versus total patient-months). . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Analysis 8.5. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 5 Exit site and tunnel infection (rate). 54
Analysis 8.6. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 6 Nausea. . . . . . . . . . 55
Analysis 8.7. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 7 Catheter removal or replacement. 55
Analysis 8.8. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 8 Nasal irritation. . . . . . . 56
56ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiAntimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Antimicrobial agents for preventing peritonitis in peritoneal
dialysis patients
Giovanni FM Strippoli1, Allison Tong2 , David W Johnson3 , Francesco Paolo Schena4, Jonathan C Craig5
1a) School of Public Health, University of Sydney, b) Cochrane Renal Group, c) Diaverum Medical Scientific office, d) Mario
Negri Sud Consortium, Italy, Westmead, Australia. 2Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead,
Australia. 3Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Australia. 4Department of Emergency andOrgan
Transplantation, University of Bari, Bari, Italy. 5(a) Cochrane Renal Group, Centre for Kidney Research, The Children’s Hospital at
Westmead, (b) School of Public Health, The University of Sydney, Westmead, Australia
Contact address: Giovanni FM Strippoli, a) School of Public Health, University of Sydney, b) Cochrane Renal Group, c) Di-
averum Medical Scientific office, d) Mario Negri Sud Consortium, Italy, Locked Bag 4001, Westmead, NSW, 2145, Australia.
Giovanni.Strippoli@diaverum.com. strippoli@negrisud.it.
Editorial group: Cochrane Kidney and Transplant Group.
Publication status and date: Edited (no change to conclusions), published in Issue 4, 2010.
Review content assessed as up-to-date: 17 December 2007.
Citation: Strippoli GFM, Tong A, Johnson DW, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dial-
ysis patients. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004679. DOI: 10.1002/14651858.CD004679.pub2.
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Peritoneal dialysis (PD) is used as substitutive treatment of renal function in a large proportion (15-50%) of the end-stage kidney disease
(ESRD) population. The major limitation is peritonitis which leads to technique failure, hospitalisation and increased mortality. Oral,
nasal, topical antibiotic prophylaxis, exit-site disinfectants and other antimicrobial interventions are used to prevent peritonitis.
Objectives
The objective of this systematic review of randomised controlled trials (RCTs) was to evaluate what evidence supports the use of different
antimicrobial approaches to prevent peritonitis in PD.
Search methods
The Cochrane CENTRAL Registry (issue 1, 2004), MEDLINE (1966-May 2003), EMBASE (1988-May 2003) and reference lists
were searched for RCTs of antimicrobial agents in PD.
Selection criteria
Trials of the following agents were included: antibiotics by any route (oral, nasal, topical), exit-site disinfectants (chlorhexidine, povidone
iodine, soap and water), vaccines, and ultraviolet germicidal devices.
Data collection and analysis
Two reviewers extracted data on the number of patients with one or more episodes and rates of peritonitis and exit-site/tunnel infection,
catheter removal, catheter replacement, technique failure, toxicity of antibiotic treatments, all-cause mortality. Statistical analyses were
performed using the random effects model and the results expressed as risk ratio (RR) with 95% confidence intervals (CI).
1Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Nineteen trials, enrolling 1949 patients met our inclusion criteria. Nasal mupirocin compared with placebo significantly reduced the
exit-site and tunnel infection rate (one trial, 2716 patient months, RR 0.58, 95% CI 0.40 to 0.85) but not peritonitis rate (one trial,
2716 patient months, RR 0.84, 95% CI 0.44 to 1.60). Perioperative intravenous antibiotics compared with no treatment significantly
reduced the risk of early peritonitis (four trials, 335 patients, RR 0.35, 95% CI 0.15 to 0.80) but not exit site and tunnel infection
(three trials, 114 patients, RR 0.32, 95% CI 0.02 to 4.81). No intervention reduced the risk of catheter removal or replacement.
Authors’ conclusions
This review demonstrates that nasal mupirocin reduces exit-site/tunnel infection but not peritonitis. Preoperative intravenous prophy-
laxis reduces early peritonitis but not exit-site/tunnel infection. No other antimicrobial interventions have proven efficacy. Given the
large number of patients on PD and the importance of peritonitis, the lack of adequately powered RCTs to inform decision making
about strategies to prevent peritonitis is striking.
P L A I N L A N G U A G E S U M M A R Y
The nasal antibiotic prophylactic mupirocin reduces exit-site/tunnel infection and preoperative intravenous antibiotic prophy-
laxis reduces early peritonitis in peritoneal dialysis
People with advanced kidney disease may be treated with peritoneal dialysis where a catheter is permanently inserted into the peritoneum
(lining around abdominal contents) through the abdominal wall and sterile fluid is drained in and out a few times each day. The most
common serious complication is infection of the peritoneum - peritonitis. This may be caused by bacteria accidentally being transferred
from the catheter. This review found that nasal mupirocin reduces exit-site/tunnel infection but not peritonitis while preoperative
intravenous antibiotic prophylaxis reduces early peritonitis but not exit-site/tunnel infection. More large scale trials are needed.
B A C K G R O U N D
Peritoneal dialysis (PD) is used as substitutive treatment of renal
function in a large proportion (15-50%) of the end-stage kidney
disease (ESRD) population. There is variability across different
countries with the United States (15%) being at the lowest and
Canada (35%) and the United Kingdom (50%) at the highest
range of PD use (Heaf 2004; Mendelssohn 2001). Because PD
and haemodialysis have similar outcomes and patients’ rating of
PD care is higher, PD should probably be used more frequently
but the risk of peritonitis may prevent this occurring (Heaf 2004).
Peritonitis, particularly due to Staphylococcus aureus, is the major
complication of PD leading to technique failure, hospitalisation
(Churchill 1997) and increasedmortality (Annigeri 2001; Digenis
1990; Piraino 2000). There has been a dramatic decrease in the
rates of peritonitis from the inception of continuous ambulatory
PD (CAPD), but rates above 0.5 episodes/patient/ year are still
common (Oxton 1994; Salusky 1997; Zelenitsky 2000). Peritoni-
tis tends to be recurrent, with a very high rate of relapse (approx-
imately 0.5 episodes/patient/year) (Vas 2001).
The incidence of peritonitis varies with age (Oxton 1994; Salusky
1997), coexisting diseases such as diabetes, PD modality (Yishak
2001), catheter design and implantation technique, connection
methodology and the presence of nasal reservoirs of S.aureus (
Golper 1996; Schaefer 2003). Immunosuppressed, African-Amer-
ican and native American PD patients are particularly at risk (Fine
1994; Holley 1993; Piraino 2002).
Different antimicrobial interventions are used to prevent peri-
tonitis. These include oral antibiotics, topical antibiotics (Thodis
2000), topical disinfectants and prophylactic treatment of S. au-
reus nasal carriage with intranasal antibiotic sprays, ointment or
powders (Piraino 2002). All of these strategies, particularly cleans-
ing and disinfection of the exit-site, are widely accepted, but prac-
tice patterns are variable and trials results are conflicting (Burkart
1997; Luzar 1990; Peacock 2002; Piraino 1997). Many societies
do not have relevant guidelines on the topic (additional Table 1).
None of these interventions are free of risks or without cost. An-
tibiotic prophylaxis carries the risk of gastrointestinal toxicity and
may be a cause of antibiotic resistance (Annigeri 2001; Bernardini
1996); it may also be ineffective when patients already have resis-
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tance to some antibiotics.
The aim of this systematic review was to evaluate the effects of the
commonly used antimicrobial interventions for the prevention of
peritonitis in PD patients. A separate analysis has been undertaken
focusing on catheter-related aspects (type, placement and insertion
technique) for the prevention of peritonitis (Strippoli 2004).
O B J E C T I V E S
To evaluate the benefits and harms of antimicrobial strategies to
prevent peritonitis in PD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs on the
effect of antimicrobial agents on the prevention of peritonitis in
PD patients were included.
Types of participants
Adult and paediatric patients undergoing PD treatment.
Types of interventions
Trials looking at the use of any antimicrobial agent were included,
whether the interventions were tested between themselves (head-
to-head) or against placebo/no treatment.
Specifically, the following antimicrobial interventions were anal-
ysed:
• Oral antibiotics
• Nasal antibiotic prophylaxis (mupirocin, rifampicin, other)
• Antistaphylococcal vaccines
• Topical disinfectants of the exit-site (povidone-iodine,
chlorhexidine, triclosan, soap and water)
• Preoperative intravenous antibiotic prophylaxis
• Germicidal systems for connection devices
• Antifungal agents
Types of outcome measures
• Peritonitis-number of patients with peritonitis and
peritonitis rate (peritonitis defined as dialysate count of > 100
cells/mm³ with > 50% being polymorphonuclear leukocytes;
peritonitis rate defined as number of episodes of peritonitis over
total patient months on PD)
• Peritonitis relapse (reoccurrence of peritonitis due to the
same organism within 2-4 weeks)
• Death due to peritonitis
• All-cause mortality
• Exit-site and tunnel infection-number of patients with exit-
site and tunnel infections and exit-site and tunnel infection rate
• Catheter removal/catheter replacement
• Technique failure (transfer from PD to haemodialysis/
transplant due to peritonitis)
• Toxicity of antibiotic treatments (nasal irritation, sneezing,
local pruritus, headache, diarrhoea, nausea, vomiting, jaundice)
• Time to first peritonitis episode
Search methods for identification of studies
Relevant trials were obtained from the following sources (see Table
2- Electronic search strategies)
1. Cochrane Renal Group specialised register of RCTs
2. Cochrane Central Register of Controlled Trials
(CENTRAL - most recent issue) for any “New” records not yet
incorporated in the specialised register
3. MEDLINE and Pre MEDLINE (1966 to May 2003) were
searched using the above terms, combined with the optimally
sensitive strategy for the identification of RCTs (Dickersin 1994)
(see Cochrane Renal Group Module).
4. EMBASE (1980 to May 2003) was searched using terms
similar to those used for MEDLINE and combined with a search
strategy for the identification of RCTs (Lefebvre 1996).
5. Reference lists of nephrology textbooks, review articles and
relevant trials.
6. Letters seeking information about unpublished or
incomplete trials to investigators known to be involved in
previous trials.
7. There was no language restriction.
Data collection and analysis
The reviewwas undertaken by five reviewers (GFMS, AT,DJ, FPS,
JC). The search strategies described were used to obtain titles and
abstracts of studies that might be relevant to the review. The ti-
tles and abstracts were screened independently (GFMS, AT), who
discarded studies that were not applicable based on the inclusion
criteria for this review; however studies and reviews that might in-
clude relevant data or information on trials were retained initially
and their full-text version was analysed. Two reviewers (GFMS,
AT) independently assessed retrieved abstracts and, were necessary,
the full text of these studies to determine study eligibility. Data
extraction was carried out independently by the same reviewers
using standard data extraction forms. It was planned that studies
reported in non-English language journals (if any) would be trans-
lated before assessment. Where more than one publication of one
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trial existed, only the publication with themost complete data was
included. Any further information or clarification required from
the authors was requested by written or electronic correspondence
and relevant data obtained in this manner were included in the
review. Disagreements were resolved in consultation (GFMS, DJ,
JC).
Study quality
The quality of included studies was assessed independently
(GFMS, AT) without blinding to authorship or journal using the
checklist developed by the Cochrane Renal Group. Discrepancies
were resolved by discussion (GFMS, JC, DJ). The quality items as-
sessed were allocation concealment, blinding of investigators, par-
ticipants and outcome assessors, intention-to-treat analysis, and
the completeness to follow-up.
Quality checklist
Allocation concealment
• Adequate (A): Randomisation method described that
would not allow investigator/participant to know or influence
intervention group before eligible participant entered in the
study
• Unclear (B): Randomisation stated but no information on
method used is available
• Inadequate (C): Method of randomisation used such as
alternate medical record numbers or unsealed envelopes; any
information in the study that indicated that investigators or
participants could influence intervention group
Blinding
• Blinding of investigators: Yes/no/not stated
• Blinding of participants: Yes/no/not stated
• Blinding of outcome assessor: Yes/no/not stated
• Blinding of data analysis: Yes/no/not stated
The above are considered not blinded if the treatment group can
be identified in > 20% of participants because of the side effects
of treatment.
Intention-to-treat analysis
• Yes: Specifically stated by authors that intention-to-treat
analysis was undertaken and this was confirmed on study
assessment.
• Yes: not specifically stated but confirmed on study
assessment
• No: Not reported and lack of intention-to-treat analysis
confirmed on study assessment (Patients who were randomised
were not included in the analysis because they did not receive the
study intervention, they withdrew from the study or were not
included because of protocol violation).
• No: Stated, but not confirmed upon study assessment
• Not stated
Completeness to follow-up
Percent of participants excluded or lost to follow-up.
Statistical assessment
Data from individual trials were analysed using the risk ratio mea-
sure (RR) and its 95% confidence intervals (CIs). When appropri-
ate, summary estimators of treatment effects were calculated using
a random effects model with RR and its 95% CIs. For each analy-
sis, the fixed effects model was also evaluated to ensure robustness
of the model chosen and susceptibility to outliers.
Where data on the number of subjects with events (e.g. number of
subjects with one or more episodes of peritonitis) were available,
the RR was calculated as the ratio of the incidence of the event
(one or more episodes) in the experimental treatment group over
the incidence in the control group. Where data on the number of
episodes were available the RR was calculated as the ratio of the
rate of the outcome (e.g. the peritonitis rate) in the experimental
treatment group (given by number of episodes of the outcome over
total patient months on PD) over the rate in the control group.
Subgroup analysis was planned to explore potential sources of
variability in observed treatment effect where possible (paediatric
versus adult population, diabetic versus non-diabetic, time on PD
before beginning of antimicrobial treatment). It was also planned
that if sufficient RCTs were identified, an attempt would be made
to assess for publication bias using a funnel plot (Egger 1997).
Heterogeneity of treatment effects between studies was formally
tested using the Q (heterogeneity χ²) and the I² statistics.
R E S U L T S
Description of studies
The combined search of MEDLINE, EMBASE, and the special-
ist registry of the Cochrane Renal Group identified 382 articles.
Of these, 338 were excluded. The major reasons for exclusion
were that the identified studies were not randomised or were ran-
domised trials evaluating other interventions (e.g. catheter-related
interventions to prevent peritonitis) (Figure 1). Full-text assess-
ment of 44 potentially eligible papers identified 19 eligible trials
(1949 patients) reported in 23 publications (Bennet-Jones 1988;
Bernardini 1996; Blowey 1994; Churchill 1988; Gadallah 2000;
4Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lye 1992; Low 1980; Luzar 1990; Mupirocin SG 1996; Nolph
1985; Perez 1992; Poole-Warren 1991; Sesso 1994; Swartz 1991;
Wai-Kei Lo 1996; Waite 1997; Wikdahl 1997; Wilson 1997;
Zimmerman 1991) . Five trial authors responded to queries about
study methods and/or requests for additional unpublished infor-
mation (Bernardini 1996; Churchill 1988; Davey 1999; Waite
1997; Wilson 1997).
Figure 1. Flow-chart indicating the number of citations retrieved by individual searches and the final
number of included trials; reasons for exclusions are provided.
Eight groups of studies were identified. In six trials (315 patients),
patients were randomised to oral prophylactic antibiotics com-
pared to placebo or no treatment (Blowey 1994; Churchill 1988;
Low 1980; Sesso 1994; Swartz 1991; Zimmerman 1991). Two
trials (289 patients) compared the use of nasal prophylactic antibi-
otics with placebo (Mupirocin SG 1996; Sesso 1994). Three trials
(393 patients) evaluated the effect of povidone iodine versus “stan-
dard care” (no treatment or soap and water) (Luzar 1990; Waite
1997;Wilson 1997), one trial (167 patients) compared an ultravi-
olet germicidal chamber for the bag outlet port versus no treatment
(Nolph 1985), and one (124 patients) compared the antistaphy-
lococcal vaccine Staphypan Berna against placebo (Poole-Warren
1991). Four trials (336 patients) compared the use of periop-
erative intravenous antibiotic prophylaxis against no treatment
(Bennet-Jones 1988; Gadallah 2000; Lye 1992; Wikdahl 1997).
There was also one trial (397 patients) which evaluated the ef-
fect of oral nystatin for the prevention of superimposed fungal
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peritonitis in patients receiving antibiotic treatment for bacterial
peritonitis (Wai-Kei Lo 1996). Finally, there were three trials (164
patients) in which antibiotic interventions were compared head to
head (Bernardini 1996; Lye 1992; Perez 1992).
Risk of bias in included studies
Assessment of the quality of the trials was difficult because many
details such as the use of intention-to-treat analysis and the num-
ber of patients lost to follow-up were difficult to ascertain or were
not provided. In general, trial quality was variable. Allocation con-
cealment was adequate in only one trial, clearly inadequate (ran-
domisation according to patient even/odd identity numbers and
alternation) in two trials and unclear in all others. Outcome as-
sessors were not stated as blinded in any of the trials. Blinding
of participants was used in 6/19 (32%) trials and blinding of in-
vestigators in 5/19 (26%) trials. Analysis was based on intention
to treat in 5/19 (26%) trials. The proportion of patients lost to
follow-up ranged from 0 to 14%.
Effects of interventions
Oral antibiotic prophylaxis
The use of oral antibiotic prophylaxis (either cotrimoxazole,
cephalexin, ofloxacin or rifampin) compared with placebo/no
treatment did not significantly reduce the risk of peritonitis,
(Analysis 1.3 (4 trials, 235 patients): RR 0.76, 95% CI 0.38 to
1.53). There was significant heterogeneity across these trials (het-
erogeneityχ² = 9.10, P =0.03, I² = 67.0%),which canbe explained
by the trial of Churchill 1988 which was the largest trial with the
highest event rate. Oral antibiotic prophylaxis did not reduce the
peritonitis rate (Analysis 1.4 (2 trials, 670 patient-months): RR
0.74, 95% CI 0.39 to 1.37), but significantly reduced the risk of
exit-site and tunnel infection (Analysis 1.5 (2 trials, 31 patients):
RR 0.29, 95% CI 0.09 to 0.97). There was no significant effect
on catheter removal or replacement (Analysis 1.7 (4 trials, 235
patients): RR 0.73, 95% CI 0.39 to 1.38) and all-cause mortal-
ity (Analysis 1.1 (4 trials, 195 patients): RR 0.84, 95% CI 0.39
to 1.79), with no significant heterogeneity across trials for any of
these analyses.
Nasal antibiotic prophylaxis
The use of nasal antibiotic prophylaxis compared with placebo/
no treatment did not reduce significantly the risk of peritonitis
(Analysis 2.2 (2 trials, 282 patients): RR 0.94, 95% CI 0.67 to
1.33). Nasal antibiotic prophylaxis also did not significantly affect
the peritonitis rate (Analysis 2.3 (1 trial, 2626 patient-months):
RR0.84, 95%CI0.44 to 1.60) or the risk of exit-site and tunnel in-
fection Analysis 2.4 (2 trials, 282 patients): RR 0.97, 95%CI 0.64
to 1.49). However, nasal mupirocin compared with placebo sig-
nificantly reduced the exit-site and tunnel infection rate (Analysis
2.5 (1 trial, 2716 patient-months): RR0.58, 95%CI 0.40 to 0.85)
and S. aureus nasal carriage (10 to 18% in mupirocin treated pa-
tients versus 48 to 61% in placebo treated patients, P < 0.001).
Nasal antibiotic prophylaxis had no effect on catheter removal or
replacement (Analysis 2.6 (2 trials, 282 patients): RR 0.89, 95%
CI 0.44 to 1.79). There was no significant heterogeneity across
trials for any of these analyses.
Peri-operative antibiotic prophylaxis
The use of peri-operative intravenous antibiotic prophylaxis com-
pared with no treatment significantly reduced the risk of early
peritonitis (less than one month from catheter insertion) (Analysis
3.1 (4 trials, 335 patients): RR 0.35 95% CI 0.15 to 0.80) but
not the risk of exit-site and tunnel infection (Analysis 3.2 (2 trials,
114 patients), RR 0.32, 95% CI 0.02 to 4.81). When outcomes
at more than one month after catheter insertion were considered,
there was no significant difference in the risk of peritonitis or exit-
site/tunnel infection.
Topical disinfectants
Topical disinfection of the exit-site with povidone iodine ointment
or dry power spray compared with no treatment or soap and water
did not significantly reduce the risk of peritonitis (Analysis 5.3 (3
trials, 382 patients): RR 0.72, 95% CI 0.46 to 1.11), exit-site/
tunnel infection (Analysis 5.2 (3 trials, 381 patients): RR 0.71,
95% CI 0.49 to 1.03), catheter removal or replacement (Analysis
5.4 (2 trials, 266 patients): RR 0.73, 95% CI 0.34 to 1.55), or
all-cause mortality (Analysis 5.1 (2 trials, 266 patients): RR 1.24,
95% CI 0.54 to 2.84), with no significant heterogeneity across
trials of any of these analyses.
Other interventions - placebo/no treatment
controlled studies
There was no significant reduction of the peritonitis rate with
other interventions including the use of a germicidal chamber for
connection devices (Analysis 6.1 (1 trial, 167 patients, 1354 pa-
tient-months): RR 1.04, 95% CI 0.71 to 1.53) and the Staphy-
pan Berna antistaphylococcal vaccine (Analysis 7.1 (1 trial, 124
patients, 1099 patient-months): RR 0.89, 95% CI 0.58 to 1.37).
Staphypan Berna was also shown to have no significant effect on
the exit-site and tunnel infection rate (Analysis 7.2 (1 trial, 1099
patient-months): RR 1.02, 95% CI 0.70 to 1.48).
One trial of oral nystatin to prevent the risk of superimposed fungal
peritonitis in patients who already presented and were receiving
treatment for bacterial peritonitis showed a significant reduction
of the rate of superimposed fungal peritonitis (Analysis 1.14 (1
trial, 397 patients, 1168 patient-months): RR 0.10, 95% CI 0.03
to 0.31) with nystatin.
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Other interventions (head to head trials)
There were insufficient data reported to evaluate the comparative
effects of different antimicrobial agents in “head to head” trials
of these agents. The only available data are reported in Table 3
- Results of head-to-head trials of antimicrobial agents to prevent
peritonitis.
Other outcomes
Summary data for all other patient-relevant outcomes (mortality
due to peritonitis, technique failure, drug-related toxicity, pruri-
tus, nausea, diarrhoea, allergy, nasal irritation, rhinitis, headache,
vomiting, technique failure) were also summarised (Table 4 -Other
outcomes analysed) but seldom reported. This analysis showed no
significant difference with any agent in relation to any of the out-
comes.
D I S C U S S I O N
This systematic review of antimicrobial prophylaxis in PDpatients
demonstrates a number of key findings.
• Topical administration of mupirocin to the anterior nares of
PD patients colonised with S. aureus significantly reduces overall
rates of exit-site and tunnel infections, but does not decrease
rates of peritonitis or catheter loss.
• Preoperative intravenous antibiotic prophylaxis significantly
reduces the risk of early peritonitis in the first few weeks (< 1
month) following Tenckhoff catheter insertion but not exit-site
and tunnel infections.
• Oral nystatin prophylaxis with each antibiotic prescription
reduces the rate of Candida peritonitis in PD patients.
• There are insufficient data reported to evaluate the
comparative effects of different antimicrobial agents in “head-to-
head” trials.
• None of the interventions studied had any significant effect
on catheter loss.
• Considering the importance of PD catheter-associated
infections as major causes of technique failure, morbidity and
mortality, RCTs of antimicrobial prophylaxis in PD patients are
rare.
To our knowledge, the present study represents the first system-
atic review assessing the relative benefits and harms of different
antimicrobial regimens in PD patients. PD catheter-associated in-
fection (peritonitis, exit-site and tunnel) is the commonest reason
for technique failure. Consequently, reported median PD tech-
nique survival rates are only of the order of 2 to 2.5 years and are
markedly lower than those of haemodialysis (Gentil 1991; Gokal
1987; Johnson 2003; Maiorca 1996; Serkes 1990). Moreover, al-
though a number of studies have demonstrated a possible sur-
vival advantage for PD compared with haemodialysis during the
first two years of dialysis, infection represents the second com-
monest cause of PD patient death (Johnson 2003). There are over
150,000 patients worldwide receiving PD, but the prospect of in-
fectious complications is amajor impediment to its broader uptake
(Diaz-Buxo 1998; Piraino 1989). This problem is compounded
further by the lack of controlled clinical trials and clinical practice
guidelines aimed to prevent infection in PD patients.
The International Society of PD (ISPD) guidelines (ISPD 2003)
currently recommend exit-site mupirocin application for all PD
patients at increased risk of S. aureus infections, including S. aureus
carriers, diabetics and immunocompromised patients. Similarly,
the Caring for Australians with Renal Impairment (CARI) guide-
lines (CARI 2003) recommend either nasal or exit-site mupirocin
prophylaxis to decrease the risk of S. aureus exit/site tunnel infec-
tions and peritonitis in PD patients (Bannister 2003; Gokal 1998;
Keane 2000).However, the present study only found evidence that
nasal application of mupirocin is effective in preventing exit-site/
tunnel infections in nasal carriers of S. aureus. Interestingly, the
benefit of mupirocin was only observed for the outcome measure
of rates of exit-site and tunnel infections, but not for the propor-
tion of patients with exit-site and tunnel infections. It is plausible
that mupirocin reduces the risk of exit-site and tunnel infections
only in patients who are frequent relapsers. Another possible ex-
planation is that the outcome of exit-site/tunnel infection rates
(rather than patients with exit-site/tunnel infections) has greater
power to detect a significant difference. This hypothesis is less
likely because the point estimate for the patient-level outcome is
close to unity. No significant effect of mupirocin on peritonitis
rates was observed.
There have been no reported RCTs, which have assessed the ef-
fectiveness of mupirocin when applied to the catheter exit-site or
when administered to PD patients other than those with nasal
colonisation by S. aureus. Moreover, the longest trial available to
date had a follow-up period of only 18 months, which is inad-
equate to assess the potentially important harmful side effect of
mupirocin resistance (Davey 1999).
Our systematic review supports the ISPD and CARI guidelines
recommendation that prophylactic antibiotic administration prior
to PD catheter insertion reduces the risk of early peritonitis but
we do not find that this intervention reduces the risk of exit-site/
tunnel infection (Bannister 2003;Gokal 1998; Keane 2000). Both
guidelines suggest that first generation cephalosporins should be
the preferred antimicrobial agent based on extrapolations from
the results of pre-operative antibiotic trials in patients without
chronic kidney disease. However, our study indicates that the evi-
dence supporting the use of first generation cephalosporins in PD
patients undergoing Tenckhoff catheter insertion is scant. In the
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present study, we identified five RCTs of different preoperative
antibiotic prophylaxis regimens, including parenteral gentamicin,
vancomycin, cephazolin and cefuroxime, with only two evaluat-
ing a first generation cephalosporin. One small trial involving 27
PD patients found that cephazolin and gentamicin were ineffec-
tive compared with no treatment (Lye 1992), whilst the largest of
the meta-analysed trials (221 patients) observed that cephazolin
was inferior to vancomycin with respect to preventing postoper-
ative catheter-associated infections (7% versus 1%, respectively P
< 0.05) (Gadallah 2000). Nevertheless, the recommendation of a
first generation cephalosporin in preference to vancomycin may
be a reasonable compromise because of the risk of vancomycin-
resistant enterococci and S. aureus (HICPAC 1995). Postoperative
infection rates in the control arms of each of the evaluated trials
were high, ranging from 12 to 46% (Bennet-Jones 1988; Gadallah
2000; Lye 1992; Wikdahl 1997), and the applicability of these
data to PD units with lower infection rates following PD catheter
insertion is unclear.
Our study also indicates that nystatin significantly reduced the
risk of Candida peritonitis in PD patients. The applicability of the
present finding is also limited, given the relatively high occurrence
rate reported in the control arm of the one large trial identified
(8.5% over 2 years) (Johnson 2003).
Our study did not find any high level evidence to support the ISPD
recommendation of regular topical exit-site disinfection with an-
tibacterial soap or a medical antiseptic to keep the exit-site clean
and to diminish resident bacteria. There are no controlled trials
evaluating the effects of antibacterial soap. Ameta-analysis of three
randomised controlled trials of topical povidone-iodine did not
show any benefit compared with non-disinfectant soap and water.
Moreover, although harms were generally inadequately reported,
one study observed that skin rashes occurred in 6% of patients
following povidone-iodine application (Wilson 1997).
The strength of this study is that it represents a comprehensive sys-
tematic review, rigid inclusion criteria for RCTs only, and a com-
prehensive MEDLINE, EMBASE and CENTRAL search. Data
extraction, data analysis and method quality assessment were per-
formed independently by two investigators, and consistency was
checked with an additional two reviewers. Furthermore, infec-
tious outcomes were separately examined in terms of rates/patient-
month and the number of patients affected in order to maximise
statistical power and to verify the robustness of statistical analyses.
Nevertheless, our analysis has several limitations. Although there
were quite a few trials which had assessed the benefits of different
antimicrobial interventions to prevent peritonitis in PD, the ma-
jority enrolled few patients over relatively short periods of follow-
up, did not adequately assess harms and were based upon sub-
optimal methodological quality standards of reporting of RCTs.
The vast majority of studies evaluated failed to specify whether
randomisation allocation was concealed, outcome assessors were
blinded or data were analysed on an intention to treat basis. These
issues, together with the small sample sizes of all but three trials
(Davey 1999; Gadallah 2000; Low 1980) reduce the strength of
the conclusions that have been drawn in this review. The possibil-
ity of a type II statistical error for some of the less frequently ob-
served outcome measures (e.g. catheter loss) cannot be excluded;
almost all analyses in this study were consistent with both clini-
cally important benefit or harm from the intervention. The ab-
sence of statistical significance in the overall risk estimates means
that we do not know whether the intervention is effective because
of problems with the trials, or whether the intervention implies
no difference in the outcome. Finally, some studies, such as those
involving prophylactic oral antibiotics, dated back to the 1980s
when peritonitis rates weremuch higher than those observed more
recently. Thus, the generalisability of these studies to contempo-
rary practice is questionable.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In conclusion, this systematic review demonstrates that
(a) eradicationof nasal S. aureus carriagewith topicalmupirocin ef-
fectively decreases the risk of exit-site and tunnel infections (prob-
ably by reducing the relapse rates in the high risk groups), but not
peritonitis or catheter loss;
(b) intravenous antibiotic administration prior to PD catheter in-
sertion effectively prevents early postoperative peritonitis but not
exit-site and tunnel infections;
(c) concomitant oral nystatin with antibiotic therapy may reduce
the occurrence of Candida peritonitis; and,
(d) no other prophylactic strategies (including prophylactic oral
antibiotics, topical disinfectants, staphylococcal vaccines or ger-
micidal chambers for connection devices) have been shown to be
effective.
Implications for research
This review also demonstrates that antimicrobial prophylaxis in
PD has been very poorly studied to date, perhaps indicating that
there are insufficient incentives to drive research in this area. There
is a pressing need for more well-designed RCTs in this area, which
adequately assess safety, as well as efficacy.
A C K N OW L E D G E M E N T S
We acknowledge the contribution of Dr. Peter Wilson, Ignatius
Fong, Gerald Coles and Cliff Holmes of the Mupirocin Study
8Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Group, David Churchill and Judy Bernardini, who responded to
our queries about their trials. We are indebted to Dr. R. Russo and
Dr.R.Curciulo of theUniversity of Bari, Italy, who commented on
the original project and provided useful background information.
Particular thanks to Dr. Paolo Strippoli, Head of the Nephrology
Unit of Ospedale “A. Perrino”, Brindisi, Italy, for his intellectual
input in this manuscript with comments on the original project
and final manuscript and providing abundant background infor-
mation and advice. We acknowledge the contribution of Narelle
Willis, Coordinator of the Cochrane Renal Group, who coordi-
nated our activities throughout the project and edited the latest
draft of this review.
R E F E R E N C E S
References to studies included in this review
Bennet-Jones 1988 {published data only}
Bennet-Jones D, Martin J, Barratt AJ, Duffy TJ, Naish PF,
Aber GM. Prophylactic gentamicin in the prevention of
early exit-site infections and peritonitis in CAPD. Advances
in Peritoneal Dialysis 1988;4:147–50.
Bernardini 1996 {published data only}
Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A
randomized trial of Staphylococcus aureus prophylaxis in
peritoneal dialysis patients: mupirocin calcium ointment
2% applied to the exit site versus cyclic oral rifampin.
American Journal of Kidney Diseases 1996;27(5):695–700.
[MEDLINE: 8629630]
Blowey 1994 {published data only}
Blowey DL, Warady BA, McFarland KS. Treatment of
Staphylococcus aureus nasal carriage in pediatric peritoneal
dialysis patients. Advances in Peritoneal Dialysis 1994;10:
297–9. [MEDLINE: 7999849]
Churchill 1988 {published data only}
Churchill DN,Oreopoulos DG, Taylor DW, Vas SI,Manuel
MA, Wu G. Peritonitis in CAPD patients - a randomized
clinical trial (RCT) of trimethoprim-sulfamethoxazole
(TMP/SMX) prophylaxis. [abstract]. Kidney International
1988;33(1):244.
∗ Churchill DN, Taylor DW, Vas SI, Singer M, Beecroft
ML, Wu G, et al. Peritonitis in continuous ambulatory
peritoneal dialysis (CAPD) patients: a randomized clinical
trial of cotrimoxazole prophylaxis. Peritoneal Dialysis
International 1988;8(2):125–8. [: EMBASE: 1988252572]
Gadallah 2000 {published data only}
Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell
L, Tatro S. Role of preoperative antibiotic prophylaxis
in preventing postoperative peritonitis in newly placed
peritoneal dialysis catheters. American Journal of Kidney
Diseases 2000;36(5):1014–9. [MEDLINE: 11054359]
Low 1980 {published data only}
Low DE, Vas SI, Oreopoulos DG, Manuel MA, Saiphoo
MM, Finer C, et al. Prophylactic cephalexin ineffective
in chronic ambulatory peritoneal dialysis. Lancet 1980;2
(8197):753–4. [MEDLINE: 6106868]
Luzar 1990 {published data only}
Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B,
et al. Exit-site care and exit-site infection in continuous
ambulatory peritoneal dialysis (CAPD): results of
a randomized multicenter trial. Peritoneal Dialysis
International 1990;10(1):25–9. [MEDLINE: 2085577]
Lye 1992 {published data only}
∗ Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the
insertion of Tenckhoff catheters. Scandinavian Journal of
Urology & Nephrology 1992;26(2):177–80. [MEDLINE:
1626207]
Lye WC, van der Straaten JC, Lee EJC. A prospective study
on the use of prophylactic antibiotics for the implantation
of tenckhoff catheters in CAPD patients [abstract]. 12th
International Congress of Nephrology; 1993 Jun 13-18;
Jerusalem, Israel. 1993:343.
Mupirocin SG 1996 {published data only}
∗ Anonymous. Nasal mupirocin prevents Staphylococcus
aureus exit-site infection during peritoneal dialysis.
Mupirocin Study Group. Journal of the American Society of
Nephrology 1996;7(11):2403–8. [MEDLINE: 8959632]
Coles GA, Mupirocin Study Group. The effect of intranasal
mupirocin on CAPD exit site infection (esi) [abstract].
Journal of the American Society of Nephrology 1994;5(3):439.
[: CN–00550592]
Davey P, Craig AM, Hau C, Malek M. Cost-effectiveness
of prophylactic nasal mupirocin in patients undergoing
peritoneal dialysis based on a randomized placebo-
controlled trial. Journal of Antimicrobial Chemotherapy
1999;43(1):105–12. [MEDLINE: 10381107]
Nolph 1985 {published data only}
Nolph KD, Prowant B, Serkes KD, Morgan LM. A
randomized multicenter clinical trial to evaluate the effects
of an ultraviolet germicidal system on peritonitis rate in
continuous ambulatory peritoneal dialysis. Peritoneal
Dialysis Bulletin 1985;5(1):19–24. [: 1985093789]
9Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Perez 1992 {published data only}
Perez-Fontain M, Rosales M, Rodriguez Carmonal A,
Moncali J, Femindez-Rivera C, Caol M, et al. Treatment
of Staphylococcus aureus nasal carriers in CAPD with
mupirocin. Advances in Peritoneal Dialysis 1992;8:242–5.
[MEDLINE: 1361797]
Poole-Warren 1991 {published data only}
Poole-Warren LA, Hallett MD, Hone PW, Burden SH,
Farrell PC. Vaccination for prevention of CAPD associated
staphylococcal infection: results of a prospective multicentre
clinical trial. Clinical Nephrology 1991;35(5):198–206.
[MEDLINE: 1855327]
Sesso 1994 {published data only}
Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D,
Cendoroglo M, et al. Effect of sodium fusidate and ofloxacin
on Staphylococcus aureus colonization and infection in
patients on continuous ambulatory peritoneal dialysis.
Clinical Nephrology 1994;41(6):370–6. [MEDLINE:
8076441]
Swartz 1991 {published data only}
Swartz R, Messana J, Starmann B, Weber M, Reynolds J.
Preventing Staphylococcus aureus infection during chronic
peritoneal dialysis. Journal of the American Society of
Nephrology 1991;2(6):1085–91. [MEDLINE: 1777589]
Wai-Kei Lo 1996 {published data only}
Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT,
Cheng IK. A prospective randomized control study of oral
nystatin prophylaxis for Candida peritonitis complicating
continuous ambulatory peritoneal dialysis. American Journal
of Kidney Diseases 1996;28(4):549–52. [MEDLINE:
8840945]
Waite 1997 {published data only}
Waite N, Webster N, Laurel M, Johnson M, Fong IW.
The efficacy of exit site povidone-iodine ointment in the
prevention of early peritoneal dialysis-related infections.
American Journal of Kidney Diseases 1997;29(5):763–8.
[MEDLINE: 9159313]
Wikdahl 1997 {published data only}
Wikdahl AM, Engman U, Stegmayr BJ, Sorenson JG.
One-dose cefuroxime i.v. and i.p. reduces microbial
growth in PD patients after catheter insertion. Nephrology
Dialysis Transplantation 1997;12(1):157–60. [MEDLINE:
9027792]
Wilson 1997 {published data only}
Wilson AP, Lewis C, O’Sullivan HO, Shetty N, Neild GH,
Mansell M. The use of povidone iodine in exit site care
for patients undergoing continuous peritoneal dialysis
(CAPD). Journal of Hospital Infection 1997;35(4):287–93.
[MEDLINE: 9152821]
Zimmerman 1991 {published data only}
∗ Zimmerman SW, Ahrens E, Johnson CA, Craig W,
Leggett J, O’Brien M, et al. Randomized controlled trial
of prophylactic rifampin for peritoneal dialysis-related
infections. American Journal of Kidney Diseases 1991;18(2):
225–31. [MEDLINE: 1867179]
Zimmerman SW, Ahrens E, Johnson CA, Craig W,
Leggett J, O’Brien M, Oxton L, Roecker E, Engeseth S.
Randomized, controlled trial of prophylactic rifampin (RIF)
for PD catheter-related infections (CRI) and peritonitis (P).
[abstract]. Kidney International 1990;37:335.
References to studies excluded from this review
de Fijter 1989 {published data only}
de Fijter CW, Verbrugh HA, Heezius HC, van BH, van
der MJ, Oe PL, Donker AJ, Verhoef J. Are intracellularly
penetrating antibiotics warranted in CAPD-related
peritonitis?. Advances in Peritoneal Dialysis 1989;5:124–7.
de Fijter CW, Verbrugh HA, Heezius HCJM, van der
MJ. Are intracellularly penetrating antibiotics warranted
in treating CAPD peritonitis caused by Staphylococcus
epidermidis?[abstract]. Nephrology Dialysis Transplantation
1989;4(8):752.
Plum 1997 {published data only}
Artic S, Busch T, Sahin K, Grabensee B, Plum J. Oral
versus intraperitoneal application of clindamycin in tunnel
infections: a prospective, randomized study in CAPD
patients [abstract]. Journal of the American Society of
Nephrology 1997;8(Program & Abstracts):260A–261A.
∗ Plum J, Artik S, Busch T, Sahin K, Grabensee B. Oral
versus intraperitoneal application of clindamycin in tunnel
infections: a prospective, randomized study in CAPD




Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP,
Bargman JM, et al. Emergence of mupirocin-resistant
Staphylococcus aureus in chronic peritoneal dialysis
patients using mupirocin prophylaxis to prevent exit-site
infection. Peritoneal Dialysis International 2001;21(6):
554–9. [MEDLINE: 11783763]
Bannister 2003
Bannister K, Walker A, Lonergan M, George C, Chow
J, Simon S, Brown F, Shaw D. Evidence for peritonitis




Burkart JM. Recommendations for clinical practice and
research needs directed at reducing morbidity and mortality
in peritoneal dialysis. Peritoneal Dialysis International 1997;
17 Suppl(3):6–8. [MEDLINE: 9304648]
CARI 2003
The CARI Guidelines: Caring for Australians with Renal
Impairment. www.kidney.org.au/cari/ (accessed: November
2003).
10Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Churchill 1997
Churchill DN, Thorpse KE, Vonesh EF, Keshaviah PR.
Lower probability of patient survival with continuous
peritoneal dialysis in the United States compared with
Canada. Canada-USA (CANUSA) Peritoneal Dialysis
Study Group. Journal of the American Society of Nephrology
1997;8(6):965–71. [MEDLINE: 9189865]
Davey 1999
Davey P, Craig AM, Hau C, Malek M. Cost-effectiveness
of prophylactic nasal mupirocin in patients undergoing
peritoneal dialysis based on a randomized, placebo-
controlled trial. Journal of Antimicrobial Chemotherapy
1999;43(1):105–12. [MEDLINE: 10381107]
Diaz-Buxo 1998
Diax-Buxo JA. Modality selection. Journal of the
American Society of Nephrology 1998;9(12 Suppl):112–7.
[MEDLINE: 11443757]
Dickersin 1994
Dickersin K, Scherer R, Lefebvre C. Identifying relevant
studies for systematic reviews. BMJ 1994;309(6964):
1286–91. [MEDLINE: 7718048]
Digenis 1990
Digenis GE, Abraham G, Savin E, Blake P, Dombros N,
Sombolos K, et al. Peritonitis-related deaths in continuous
ambulatory peritoneal dialysis (CAPD) patients. Peritoneal
Dialysis International 1990;10(1):45–7. [MEDLINE:
2085582]
Egger 1997
Egger M, Davey-Smith G, Schneider M, Minder C. Bias
in meta-analysis detected by a simple graphical test. BMJ
1997;315(7109):629–34. [MEDLINE: 9310563]
Fine 1994
Fine A, Cox D, Bouw M. Higher incidence of peritonitis
in native Canadians on continuous ambulatory peritoneal
dialysis. Peritoneal Dialysis International 1994;14(3):
227–30. [MEDLINE: 7948232]
Gentil 1991
Gentil MA, Carriazo A, Pavon MI, Rosado M, Castillo D,
Ramos B, et al. Comparison of survival in continuous
ambulatory peritoneal dialysis and hospital haemodialysis:
a multicentric study. Nephrology Dialysis Transplantation
1991;6(6):444–51. [MEDLINE: 1876287]
Gokal 1987
Gokal R, Jakubowski C, King J, Hunt L, Bogle S, Baillod
R, et al. Outcome in patients on continuous ambulatory
peritoneal dialysis and haemodialysis: 4-year analysis of
a prospective multicentre study. Lancet 1987;2(8568):
1105–9. [MEDLINE: 2890018]
Gokal 1998
Gokal R, Alexander S, Ash S, Chen TW, Danielson
A, Holmes C, et al. Peritoneal catheters and exit-site
practices toward optimum peritoneal access: 1998 update.
(Official report from the International Society for Peritoneal
Dialysis). Peritoneal Dialysis International 1998;18(1):
11–33. [MEDLINE: 9527026]
Golper 1996
Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett
DK, Hamilton RW, et al. Risk factors for peritonitis in
long-term peritoneal dialysis: the Network 9 peritonitis
and catheter survival studies. Academic Subcommittee
of the Steering Committee of the Network 9 Peritonitis
and Catheter Survival Studies. American Journal of Kidney
Diseases 1996;28(3):428–36. [MEDLINE: 8804243]
Heaf 2004
Heaf J. Underutilization of peritoneal dialysis. JAMA 2004;
291(6):740–2. [MEDLINE: 14871920]
HICPAC 1995
Anonymous. Recommendations for preventing the spread
of vancomycin resistance. Hospital Infection Control
Practices Advisory Committee (HICPAC). Infection Control
& Hospital Epidemiology 1995;16(2):105–13. [MEDLINE:
7759811]
Holley 1993
Holley JL, Bernardini J, Piraino B. A comparison of
peritoneal dialysis-related infections in black and white
patients. Peritoneal Dialysis International 1993;13(1):45–9.
[MEDLINE: 8443276]
ISPD 2003




Johnson DW. Peritoneal Dialysis. ANZDATA Registry
Report. McDonald SP, Russ GR (eds), 2003.
Keane 2000
Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper
TA, Holmes CJ, et al. Adult peritoneal dialysis-related
peritonitis treatment recommendations: 2000 update.
Peritoneal Dialysis International 2000;20(4):396–411.
[MEDLINE: 11007371]
Lefebvre 1996
Lefebvre C, McDonald S. Development of a sensitive
search strategy for reports of randomized controlled trials
in EMBASE. Fourth International Cochrane Colloquium;
1996 Oct 20-24; Adelaide (Australia). 1996.
Maiorca 1996
Maiorca R, Cancarini GC, Zubani R, Camerini C, Manili L,
Brunori G, et al. CAPD viability: a long-term comparison
with hemodialysis. Peritoneal Dialysis International 1996;16
(3):267–87. [MEDLINE: 8761542]
Mendelssohn 2001
Mendelssohn DC, Mullaney SR, Jung B, Blake PG, Mehta
RL. What do American nephrologists think about dialysis
modality selection?. American Journal of Kidney Diseases
2001;37(1):22–9. [MEDLINE: 11136163]
Oxton 1994
Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk
factors for peritoneal dialysis-related infections. Peritoneal
Dialysis International 1994;14(2):137–44. [MEDLINE:
8043666]
11Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Peacock 2002
Peacock SJ,Mandal S, Bowler IC. Preventing Staphylococcus
aureus infection in the renal unit. Qjm 2002;35(6):405–10.
[MEDLINE: 12037249]
Piraino 1989
Piraino B, Bernardini J, Sorkin M. Catheter infections as a
factor in the transfer of continuous ambulatory peritoneal
dialysis patients to hemodialysis. American Journal of Kidney
Diseases 1989;13(5):365–9. [MEDLINE: 2719024]
Piraino 1997
Piraino B. Infectious complications of peritoneal dialysis.
Peritoneal Dialysis International 1997;17 Suppl(3):15–8.
[MEDLINE: 9304651]
Piraino 2000
Piraino B. Staphylococcus aureus infections in dialysis
patients: focus on prevention. ASAIO Journal 2000;46(6):
13–7. [MEDLINE: 11110288]
Piraino 2002
Piraino B. ADEMEX: how should it change our practice?
Adequacy of peritoneal dialysis in Mexico. Peritoneal
Dialysis International 2002;22(5):552–4. [MEDLINE:
9773798]
Salusky 1997
Salusky IB, Holloway M. Selection of peritoneal dialysis for
pediatric patients. Peritoneal Dialysis International 1997;17
Suppl(3):35–7. [MEDLINE: 9304656]
Schaefer 2003
Schaefer F. Management of peritonitis in children receiving
chronic peritoneal dialysis. Paediatric Drugs 2003;5(5):
315–25. [MEDLINE: 12716218]
Serkes 1990
Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F.
Comparison of patient and technique survival in continuous
ambulatory peritoneal dialysis (CAPD) and hemodialysis: a
multicenter study. Peritoneal Dialysis International 1990;10
(1):15–9. [MEDLINE: 2085575]
Strippoli 2004
Strippoli GFM, Tong A, Johnson D, Schena FP, Craig
JC. Catheter type, placement and insertion techniques
for preventing peritonitis in peritoneal dialysis patients.
Cochrane Database of Systematic Reviews 2004, Issue 4.
[DOI: 10.1002/14651858.CD004680.pub2]
Thodis 2000
Thodis E, Passadakis P, Panagoutsos S, Bacharaki D,
Euthimiadou A, Vargemezis V. The effectiveness of
mupirocin preventing Staphylococcus aureus in catheter-
related infections in peritoneal dialysis. Advances in
Peritoneal Dialysis 2000;16:257–61. [MEDLINE:
11045306]
Vas 2001
Vas S, Oreopoulos DG. Infections in patients undergoing
peritoneal dialysis. Infectious Disease Clinics of North
America 2001;15(3):743–74. [MEDLINE: 11570140]
Yishak 2001
Yishak A, Bernardini J, Fried L, Piraino B. The outcome
of peritonitis in patients on automated peritoneal
dialysis. Advances in Peritoneal Dialysis 2001;17:205–8.
[MEDLINE: 11510277]
Zelenitsky 2000
Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, et
al. Analysis of microbiological trends in peritoneal dialysis-
related peritonitis from 1991 to 1998. American Journal
of Kidney Diseases 2000;36(5):1009–13. [MEDLINE:
11054358]
References to other published versions of this review
Strippoli 2003
Strippoli GFM, Tong A, Johnson D, Schena FP, Craig
JC. Anti-infective (antiseptics and antibiotics) agents
for preventing peritonitis in peritoneal dialysis patients.
Cochrane Database of Systematic Reviews 2003, Issue 4.
[DOI: 10.1002/14651858.CD004679]
∗ Indicates the major publication for the study
12Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bennet-Jones 1988
Methods RCT
Randomization: method not stated
Participants 27 patients
Mean age: 52.7 ± 18.6 versus 53.1 ± 13.0 years
Proportion of diabetic patients: 0%
Interventions Gentamicin (i.v.) 1.5 mg/kg at time of catheter placement versus none
Outcomes Peritonitis, exit-site/tunnel infection, catehter removal
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Bernardini 1996
Methods RCT
Randomization: method not stated
Participants 82 patients
Mean age: NA
Proportion of diabetic patients: 34%
Interventions Mupirocin (2%) nasal ointment, daily applications, versus rifampin (oral) 300 mg x 2/day x 5 days, every
3 months
Outcomes All-cause mortality, peritonitis, exit-site/tunnel infection, catheter removal/replacement
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Blowey 1994
Methods RCT
Randomization: method not stated
Participants 15 patients
Mean age: 11.5 (8-21) years
Proportion of diabetic patients: NA
Interventions Rifampicin 20 mg/kg/day in 2 doses for 5 days + bacitracin (nasal) 2 times/day x 7 days versus none
Outcomes Peritonitis, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Churchill 1988
Methods RCT
Randomization: method not stated
Participants 105 patients
Mean age: NA
Proportion of diabetic patients: NA
Interventions Trimethoprim 160 mg/sulfamethoxazole 800 mg/day x 12 months versus none
Outcomes All-cause mortality, peritonitis, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Gadallah 2000
Methods RCT
Randomization: method not stated
Inadequate allocation concealment
Trial with three arms
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Gadallah 2000 (Continued)
Participants 221 patients
Mean age: 47 (15-76) versus 48 (28-81) versus 44 (18-77) years
Proportion of diabetic patients: 23%
Interventions Vancomycin (i.v.) 1000 mg 12 h before catheter placement versus cefazolin (i.v.) 100 mg 3 h before
catheter placement versus no treatment
Outcomes Peritonitis, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? High risk C - Inadequate
Low 1980
Methods RCT
Randomization: method not stated
Participants 50 patients
Mean age: NA
Proportion of diabetic patients: NA




Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Luzar 1990
Methods RCT
Randomization: method not stated
Participants 127 patients
Mean age: NA
Proportion of diabetic patients: 22%
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Luzar 1990 (Continued)
Interventions Povidone iodine (20 g/L) and nonocclusive dressing 2-3 times/week versus none
Outcomes All-cause mortality, peritonitis, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Lye 1992
Methods RCT
Randomization: method not stated
Participants 50 patients
Mean age: 56.0 ± 14.3 versus 52.3 ± 14.0 years
Proportion of diabetic patients: 30%
Interventions Cefazolin (i.v.) t00 mg and gentamicin (i.v.) 80 mg 1 hour before catheter placement versus none
Outcomes All-cause mortality, peritonitis, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Mupirocin SG 1996
Methods RCT
Randomization: method not stated
Participants 267 patients
Mean age: 60.3 years
Proportion of diabetic patients: 20%
Interventions Mupirocin (2%) nasal ointment b.i.d. x 5 days, every 1 month versus placebo
Outcomes All-cause mortality, peritonitis, peritonitis rate, exit-site/tunnel infection, exit-site/tunnel infection rate,
catheter removal or replacement
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Mupirocin SG 1996 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Nolph 1985
Methods RCT
Randomization: method not stated
Participants 167 patients
Mean age: 49 ± 14 years
Proportion of diabetic patients: 20%
Interventions Ultraviolet germicidal chamber for bag outlet port versus none
Outcomes All-cause mortality, peritonitis, peritonitix rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Perez 1992
Methods RCT
Randomization: method not stated
Participants 32 patients
Mean age: 51 ± 15 versus 48 ± 21 years
Proportion of diabetic patients: 16%
Interventions Mupirocin (2%) nasal ointment t.i.d. x 7 days versus neomycin sulphate (0.1%) nasal ointment t.i.d. x 7
days
Outcomes All-cause mortality, peritonitis, peritonitis rate, exit-site/tunnel infection
Notes
Risk of bias
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Perez 1992 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Poole-Warren 1991
Methods RCT
Randomization: method not stated; patients randomly assigned by an independent third party
Participants 124 patients
Mean age: 51 ± 11 versus 52 ± 14 years
Proportion of diabetic patients: 17%
Interventions Staphypan Berna versus placebo
Outcomes Peritonitis, peritonitis rate, exit-site/tunnel infection and exit-site/tunnel infection rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Sesso 1994
Methods RCT
Randomization: method not stated
Participants 31 patients
Mean age 43.1 ± 3.8 versus 36.6 ± 4.6
Proportion of diabetic patients: 23%
Interventions Ofloxacin 200 mg/day x 5 days versus Sodium fusidate (2%) nasal ointment twice daily x 5 days versus
placebo
Outcomes All-cause mortality, peritonitis, peritonitis rate, exit-site/tunnel infection, exit-site/tunnel infection rate,
catheter removal or replacement, nasal irritation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Sesso 1994 (Continued)
Allocation concealment? Unclear risk B - Unclear
Swartz 1991
Methods RCT
Randomization: method not stated
Participants 59 patients
Mean age 49 ± 3.4 versus 51 ± 3.1
Proportion of diabetic patients: 34%
Interventions Trimethoprim/sulfamethoxazole (low dose) or cephalexin (250 mg) or clindamycin (300 mg) versus none
Outcomes All-cause mortality, peritonitis rate, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Wai-Kei Lo 1996
Methods RCT
Randomization: method not stated
Inadequate allocation concealment.
Participants 397 patients
Mean age: 48.4 ± 14.5 versus 48.5 ± 14.2 years
Proportion of diabetic patients: 17%
Interventions Nystatin 500,000 units x 4/day (whenever antibiotics were administered for bacterial peritonitis) versus
none




Bias Authors’ judgement Support for judgement
Allocation concealment? High risk C - Inadequate
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Waite 1997
Methods RCT
Randomization: method not stated
Participants 117 patients
Mean age: 54.4 ± 15.1 versus 53.2 ± 14.5 years
Proportion of diabetic patients: 33%
Interventions Povidone iodine (10%) ointment 3.5 g at every dressing change versus none
Outcomes All-cause mortality, peritonitis, exit-site/tunnel infection, catheter removal or replacement
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Wikdahl 1997
Methods RCT
Randomization: method not stated
Participants 38 patients
Mean age: 56 (33-84) versus 61 (38-84) years
Proportion of diabetic patients: 34%
Interventions Cefuroxime (i.v.) 1.5 g at time of catehter placement + 250 mg i.p. in first dialysis bag versus none
Outcomes Peritonitis, exit-site/tunnel infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Wilson 1997
Methods RCT
Randomization: method not stated
Participants 149 patients
Mean age: 53 (18-82) versus 51 (21-76) years
Proportion of diabetic patients: NA
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Wilson 1997 (Continued)
Interventions Povidone iodine (2.5%) dry powder spray at every dressing change versus none




Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Zimmerman 1991
Methods RCT
Randomization: method not stated
Participants 64 patients
Mean age: 53 ± 3 versus 55 ± 4 years
Proportion of diabetic patients: 41%
Interventions Rifampin 300 mg x 2/day x 5 days, every 3 months versus none
Outcomes Peritonitis, peritonitis rate, catheter removal or replacement, toxicity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
de Fijter 1989 Treatment study not prevention.
Plum 1997 Treatment study not prevention.
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D A T A A N D A N A L Y S E S
Comparison 1. Oral antibiotics versus none




participants Statistical method Effect size
1 Mortality (all cause) 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Any versus placebo/no
treatment
4 195 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.39, 1.79]
2 Mortality due to peritonitis 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Cotrimoxazole versus
placebo/no treatment
1 Risk Ratio (M-H, Random, 95% CI) 4.39 [0.22, 89.20]
3 Peritonitis (number of patients
with one or more episodes)




2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Any versus placebo/no
treatment (excluding nistatin)
2 670 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.39, 1.37]
5 Exit-site/tunnel infection
(number of patients with one
or more episodes)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Any versus placebo/no
treatment
2 31 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.09, 0.97]
6 Exit-site/tunnel infection rate
(episodes/total patient-months
on PD)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Any versus placebo/no
treatment
1 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.08, 2.31]
7 Catheter removal or replacement 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Any versus placebo/no
treatment
4 235 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.39, 1.38]
8 Pruritus (generalised) 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Rifampin (oral) versus
none
1 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.13, 71.00]
9 Diarrhoea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Rifampin (oral) versus
none
1 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 1.58]
10 Nausea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
10.1 Rifampin (oral) versus
none
1 Risk Ratio (M-H, Random, 95% CI) 9.00 [0.50, 160.59]
11 Allergy 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.1 Rifampin (oral) versus
none
1 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.25, 100.20]
12 Nasal irritation 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
12.1 Ofloxacin (oral) versus
placebo
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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13 Fungal peritonitis (number
of patients with one or more
episodes)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
13.1 Nistatin versus none 1 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.20, 1.44]
14 Fungal peritonitis rate
(episodes/patient-months on
PD)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
14.1 Nistatin (oral) versus
none
1 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.31]
Comparison 2. Nasal antibiotics versus none




participants Statistical method Effect size
1 Mortality (all cause) 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Any versus placebo 2 282 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.52, 1.47]
2 Peritonitis (number of patients
with peritonitis)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only




1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Mupirocin (nasal) versus
placebo
1 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.44, 1.60]
4 Exit site and tunnel infection
(number of patients with exit
site and tunnel infection)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 any versus placebo 2 282 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.64, 1.49]
5 Exit site and tunnel infection
rate (episodes/patient-month
versus total patient-months)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Mupirocin versus placebo 1 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.40, 0.85]
6 Catheter removal or replacement 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Any versus placebo 2 282 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.44, 1.79]
7 Nasal irritation/rhinitis 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Fusidate versus placebo 1 Risk Ratio (M-H, Random, 95% CI) 2.1 [0.10, 44.40]
7.2 Mupirocin versus placebo 1 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.27, 2.09]
8 Headache 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 Diarrhoea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
10 Nausea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
11 Vomiting 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
12 Pruritus 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
13 Peritonitis 2 282 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.67, 1.33]
14 Peritonitis rate 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
15 Exit-site/tunnel infection 2 282 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.64, 1.49]
16 Exit-site/tunnel infection rate 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Comparison 3. Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials)




participants Statistical method Effect size
1 Peritonitis (number of patients
with peritonitis)
4 335 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.15, 0.80]
2 Exit site and tunnel infection
(number of patients with exit
site and tunnel infection)
3 114 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.02, 4.81]
3 Catheter removal 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Gentamicin (IV) versus
no treatment (preoperative)
1 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.02, 8.06]
4 Death 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 4. Peri-operative IV prophylaxis head-to-head




participants Statistical method Effect size
1 Peritonitis (number of patients
with peritonitis)
0 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Any versus placebo/no
treatment (preoperative)
0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Exit site and tunnel infection
(number of patients with exit
site and tunnel infection)
0 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Any versus placebo/no
treatment (preoperative)
0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Catheter removal 0 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Gentamicin (IV) versus
no treatment (preoperative)
0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Topical disinfectants versus none




participants Statistical method Effect size
1 Mortality (all cause) 2 266 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.54, 2.84]
2 Exit site and tunnel infection
(number of patients with exit
site and tunnel infection)
3 381 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.49, 1.03]
3 Peritonitis (number of patients
with peritonitis)
3 382 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.46, 1.11]
4 Catheter removal or replacement 2 266 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.34, 1.55]
5 Technique failure 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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6 Pruritus (local) 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Germicidal chamber versus none








1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Mortality (all cause) 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 7. Antistaphylococcal vaccine (Staphypan) versus placebo








1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Exit site and tunnel infection
rate (episodes/patient-month
versus total patient-months)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 8. Antibiotic prophylaxis head-to-head agents




participants Statistical method Effect size
1 Mortality (all cause) 2 100 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.14, 16.15]
1.1 Fusidate versus ofloxacin 1 18 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.02, 7.24]
1.2 Mupirocin versus rifampin 1 82 Risk Ratio (M-H, Random, 95% CI) 4.0 [0.47, 34.28]
2 Exit site and tunnel infection
(number of patients with exit
site and tunnel infection)
3 305 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.45, 2.03]
2.1 Fusidate versus ofloxacin 1 18 Risk Ratio (M-H, Random, 95% CI) 2.5 [0.65, 9.69]
2.2 Vancomicin versus
cefazolin (preoperative)
1 205 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.13, 1.93]
2.3 Mupirocin versus rifampin 1 82 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.43, 1.66]
3 Peritonitis (number of patients
with peritonitis)
2 287 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.03, 5.73]
3.1 Vancomicin versus
cefazolin (preoperative)
1 205 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 0.85]
3.2 Mupirocin versus rifampin 1 82 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.67, 2.33]
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2 1235 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.51, 1.48]
4.1 Fusidate versus ofloxacin 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Mupirocin versus
neomicin sulphate
1 209 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.20, 2.58]
4.3 Mupirocin versus rifampin 1 1026 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.51, 1.62]
5 Exit site and tunnel infection
(rate)
2 1173 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.30, 4.72]
5.1 Fusidate versus ofloxacin 1 147 Risk Ratio (M-H, Random, 95% CI) 2.96 [0.62, 14.19]
5.2 Mupirocin versus rifampin 1 1026 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.38, 1.24]
6 Nausea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Mupirocin versus rifampin 1 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 2.00]
7 Catheter removal or replacement 2 100 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.45, 2.46]
7.1 Fusidate versus ofloxacin 1 18 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.41, 4.33]
7.2 Mupirocin versus rifampin 1 82 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.23, 2.77]
8 Nasal irritation 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Fusidate versus ofloxacin 1 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.14, 65.16]
Analysis 1.1. Comparison 1 Oral antibiotics versus none, Outcome 1 Mortality (all cause).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 1 Mortality (all cause)








1 Any versus placebo/no treatment
Blowey 1994 0/7 2/8 6.9 % 0.23 [ 0.01, 4.02 ]
Churchill 1988 5/56 3/49 30.2 % 1.46 [ 0.37, 5.79 ]
Sesso 1994 1/9 1/7 8.6 % 0.78 [ 0.06, 10.37 ]
Swartz 1991 5/29 7/30 54.3 % 0.74 [ 0.26, 2.07 ]
Subtotal (95% CI) 101 94 100.0 % 0.84 [ 0.39, 1.79 ]
Total events: 11 (Treatment), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.48, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Oral antibiotics versus none, Outcome 2 Mortality due to peritonitis.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 2 Mortality due to peritonitis








1 Cotrimoxazole versus placebo/no treatment
Churchill 1988 2/56 0/49 4.39 [ 0.22, 89.20 ]
0.01 0.1 1 10 100
Favours treatment Favours control
Analysis 1.3. Comparison 1 Oral antibiotics versus none, Outcome 3 Peritonitis (number of patients with
one or more episodes).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 3 Peritonitis (number of patients with one or more episodes)








Churchill 1988 33/56 22/49 36.6 % 1.31 [ 0.90, 1.92 ]
Low 1980 2/25 6/25 14.2 % 0.33 [ 0.07, 1.50 ]
Sesso 1994 4/9 3/7 19.9 % 1.04 [ 0.34, 3.19 ]
Zimmerman 1991 8/32 17/32 29.4 % 0.47 [ 0.24, 0.93 ]
Total (95% CI) 122 113 100.0 % 0.76 [ 0.38, 1.53 ]
Total events: 47 (Treatment), 48 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 9.10, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.76 (P = 0.45)
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.4. Comparison 1 Oral antibiotics versus none, Outcome 4 Peritonitis rate (episodes/patient-
months on PD).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 4 Peritonitis rate (episodes/patient-months on PD)








1 Any versus placebo/no treatment (excluding nistatin)
Sesso 1994 5/72 6/96 29.7 % 1.11 [ 0.35, 3.50 ]
Zimmerman 1991 10/231 19/271 70.3 % 0.62 [ 0.29, 1.30 ]
Subtotal (95% CI) 303 367 100.0 % 0.74 [ 0.39, 1.37 ]
Total events: 15 (Treatment), 25 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.33)
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Analysis 1.5. Comparison 1 Oral antibiotics versus none, Outcome 5 Exit-site/tunnel infection (number of
patients with one or more episodes).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 5 Exit-site/tunnel infection (number of patients with one or more episodes)








1 Any versus placebo/no treatment
Blowey 1994 0/7 2/8 17.1 % 0.23 [ 0.01, 4.02 ]
Sesso 1994 2/9 5/7 82.9 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 16 15 100.0 % 0.29 [ 0.09, 0.97 ]
Total events: 2 (Treatment), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
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Analysis 1.6. Comparison 1 Oral antibiotics versus none, Outcome 6 Exit-site/tunnel infection rate
(episodes/total patient-months on PD).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 6 Exit-site/tunnel infection rate (episodes/total patient-months on PD)








1 Any versus placebo/no treatment
Sesso 1994 2/73 4/64 0.44 [ 0.08, 2.31 ]
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Analysis 1.7. Comparison 1 Oral antibiotics versus none, Outcome 7 Catheter removal or replacement.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 7 Catheter removal or replacement








1 Any versus placebo/no treatment
Churchill 1988 7/56 9/49 49.2 % 0.68 [ 0.27, 1.69 ]
Low 1980 3/25 1/25 8.5 % 3.00 [ 0.33, 26.92 ]
Sesso 1994 3/9 3/7 25.7 % 0.78 [ 0.22, 2.74 ]
Zimmerman 1991 2/32 5/32 16.6 % 0.40 [ 0.08, 1.91 ]
Subtotal (95% CI) 122 113 100.0 % 0.73 [ 0.39, 1.38 ]
Total events: 15 (Treatment), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.20, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
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Analysis 1.8. Comparison 1 Oral antibiotics versus none, Outcome 8 Pruritus (generalised).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 8 Pruritus (generalised)








1 Rifampin (oral) versus none
Zimmerman 1991 1/32 0/32 3.00 [ 0.13, 71.00 ]
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Analysis 1.9. Comparison 1 Oral antibiotics versus none, Outcome 9 Diarrhoea.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 9 Diarrhoea








1 Rifampin (oral) versus none
Zimmerman 1991 0/32 5/32 0.09 [ 0.01, 1.58 ]
0.005 0.1 1 10 200
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Analysis 1.10. Comparison 1 Oral antibiotics versus none, Outcome 10 Nausea.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 10 Nausea








1 Rifampin (oral) versus none
Zimmerman 1991 4/32 0/32 9.00 [ 0.50, 160.59 ]
0.005 0.1 1 10 200
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Analysis 1.11. Comparison 1 Oral antibiotics versus none, Outcome 11 Allergy.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 11 Allergy








1 Rifampin (oral) versus none
Zimmerman 1991 2/32 0/32 5.00 [ 0.25, 100.20 ]
0.005 0.1 1 10 200
Favours treatment Favours control
Analysis 1.12. Comparison 1 Oral antibiotics versus none, Outcome 12 Nasal irritation.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 12 Nasal irritation








1 Ofloxacin (oral) versus placebo
Sesso 1994 0/9 0/7 Not estimable
0.01 0.1 1 10 100
Favours treatment Favours control
32Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.13. Comparison 1 Oral antibiotics versus none, Outcome 13 Fungal peritonitis (number of
patients with one or more episodes).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 13 Fungal peritonitis (number of patients with one or more episodes)








1 Nistatin versus none
Wai-Kei Lo 1996 6/199 11/198 0.54 [ 0.20, 1.44 ]
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Analysis 1.14. Comparison 1 Oral antibiotics versus none, Outcome 14 Fungal peritonitis rate
(episodes/patient-months on PD).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 1 Oral antibiotics versus none
Outcome: 14 Fungal peritonitis rate (episodes/patient-months on PD)








1 Nistatin (oral) versus none
Wai-Kei Lo 1996 4/894 12/274 0.10 [ 0.03, 0.31 ]
0.02 0.1 1 10 50
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Analysis 2.1. Comparison 2 Nasal antibiotics versus none, Outcome 1 Mortality (all cause).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 1 Mortality (all cause)








1 Any versus placebo
Mupirocin SG 1996 22/134 25/133 100.0 % 0.87 [ 0.52, 1.47 ]
Sesso 1994 0/9 0/6 Not estimable
Subtotal (95% CI) 143 139 100.0 % 0.87 [ 0.52, 1.47 ]
Total events: 22 (Treatment), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
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Analysis 2.2. Comparison 2 Nasal antibiotics versus none, Outcome 2 Peritonitis (number of patients with
peritonitis).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 2 Peritonitis (number of patients with peritonitis)








1 Any versus placebo
Mupirocin SG 1996 43/134 44/133 97.5 % 0.97 [ 0.69, 1.37 ]
Sesso 1994 1/9 2/6 2.5 % 0.33 [ 0.04, 2.91 ]
Subtotal (95% CI) 143 139 100.0 % 0.94 [ 0.67, 1.33 ]
Total events: 44 (Treatment), 46 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 2.3. Comparison 2 Nasal antibiotics versus none, Outcome 3 Peritonitis rate (episodes/patient-
month versus total patient-months).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 3 Peritonitis rate (episodes/patient-month versus total patient-months)








1 Mupirocin (nasal) versus placebo
Mupirocin SG 1996 18/1390 19/1236 0.84 [ 0.44, 1.60 ]
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Analysis 2.4. Comparison 2 Nasal antibiotics versus none, Outcome 4 Exit site and tunnel infection
(number of patients with exit site and tunnel infection).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 4 Exit site and tunnel infection (number of patients with exit site and tunnel infection)








1 any versus placebo
Mupirocin SG 1996 26/134 25/133 73.1 % 1.03 [ 0.63, 1.69 ]
Sesso 1994 5/9 4/6 26.9 % 0.83 [ 0.37, 1.88 ]
Subtotal (95% CI) 143 139 100.0 % 0.97 [ 0.64, 1.49 ]
Total events: 31 (Treatment), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
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Analysis 2.5. Comparison 2 Nasal antibiotics versus none, Outcome 5 Exit site and tunnel infection rate
(episodes/patient-month versus total patient-months).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 5 Exit site and tunnel infection rate (episodes/patient-month versus total patient-months)








1 Mupirocin versus placebo
Mupirocin SG 1996 42/1390 64/1236 0.58 [ 0.40, 0.85 ]
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Analysis 2.6. Comparison 2 Nasal antibiotics versus none, Outcome 6 Catheter removal or replacement.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 6 Catheter removal or replacement








1 Any versus placebo
Mupirocin SG 1996 8/134 9/133 58.0 % 0.88 [ 0.35, 2.22 ]
Sesso 1994 4/9 3/6 42.0 % 0.89 [ 0.30, 2.63 ]
Subtotal (95% CI) 143 139 100.0 % 0.89 [ 0.44, 1.79 ]
Total events: 12 (Treatment), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
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Analysis 2.7. Comparison 2 Nasal antibiotics versus none, Outcome 7 Nasal irritation/rhinitis.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 7 Nasal irritation/rhinitis








1 Fusidate versus placebo
Sesso 1994 1/9 0/6 2.10 [ 0.10, 44.40 ]
2 Mupirocin versus placebo
Mupirocin SG 1996 6/134 8/133 0.74 [ 0.27, 2.09 ]
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Analysis 2.8. Comparison 2 Nasal antibiotics versus none, Outcome 8 Headache.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 8 Headache








Mupirocin SG 1996 2/134 2/133 0.99 [ 0.14, 6.94 ]
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Analysis 2.9. Comparison 2 Nasal antibiotics versus none, Outcome 9 Diarrhoea.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 9 Diarrhoea








Mupirocin SG 1996 5/134 3/133 1.65 [ 0.40, 6.78 ]
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Analysis 2.10. Comparison 2 Nasal antibiotics versus none, Outcome 10 Nausea.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 10 Nausea








Mupirocin SG 1996 2/134 2/133 0.99 [ 0.14, 6.94 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 2.11. Comparison 2 Nasal antibiotics versus none, Outcome 11 Vomiting.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 11 Vomiting








Mupirocin SG 1996 6/134 2/133 2.98 [ 0.61, 14.49 ]
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Analysis 2.12. Comparison 2 Nasal antibiotics versus none, Outcome 12 Pruritus.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 12 Pruritus








Mupirocin SG 1996 3/134 2/133 1.49 [ 0.25, 8.77 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 2.13. Comparison 2 Nasal antibiotics versus none, Outcome 13 Peritonitis.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 13 Peritonitis








Mupirocin SG 1996 43/134 44/133 97.5 % 0.97 [ 0.69, 1.37 ]
Sesso 1994 1/9 2/6 2.5 % 0.33 [ 0.04, 2.91 ]
Total (95% CI) 143 139 100.0 % 0.94 [ 0.67, 1.33 ]
Total events: 44 (Treatment), 46 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 2.14. Comparison 2 Nasal antibiotics versus none, Outcome 14 Peritonitis rate.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 14 Peritonitis rate








Mupirocin SG 1996 18/1390 19/1236 0.84 [ 0.44, 1.60 ]
0.2 0.5 1 2 5
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Analysis 2.15. Comparison 2 Nasal antibiotics versus none, Outcome 15 Exit-site/tunnel infection.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 15 Exit-site/tunnel infection








Mupirocin SG 1996 26/134 25/133 73.1 % 1.03 [ 0.63, 1.69 ]
Sesso 1994 5/9 4/6 26.9 % 0.83 [ 0.37, 1.88 ]
Total (95% CI) 143 139 100.0 % 0.97 [ 0.64, 1.49 ]
Total events: 31 (Treatment), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
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Analysis 2.16. Comparison 2 Nasal antibiotics versus none, Outcome 16 Exit-site/tunnel infection rate.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 2 Nasal antibiotics versus none
Outcome: 16 Exit-site/tunnel infection rate








Mupirocin SG 1996 42/1390 64/1236 0.58 [ 0.40, 0.85 ]
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Analysis 3.1. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled
trials), Outcome 1 Peritonitis (number of patients with peritonitis).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials)
Outcome: 1 Peritonitis (number of patients with peritonitis)








Bennet-Jones 1988 1/13 6/13 16.7 % 0.17 [ 0.02, 1.20 ]
Gadallah 2000 7/148 10/73 62.9 % 0.35 [ 0.14, 0.87 ]
Lye 1992 2/25 1/25 12.1 % 2.00 [ 0.19, 20.67 ]
Wikdahl 1997 0/18 4/20 8.2 % 0.12 [ 0.01, 2.13 ]
Total (95% CI) 204 131 100.0 % 0.35 [ 0.15, 0.80 ]
Total events: 10 (Treatment), 21 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 3.22, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 2.49 (P = 0.013)
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Analysis 3.2. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled
trials), Outcome 2 Exit site and tunnel infection (number of patients with exit site and tunnel infection).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials)
Outcome: 2 Exit site and tunnel infection (number of patients with exit site and tunnel infection)








Bennet-Jones 1988 0/13 7/13 39.1 % 0.07 [ 0.00, 1.06 ]
Lye 1992 6/25 7/25 60.9 % 0.86 [ 0.34, 2.19 ]
Wikdahl 1997 0/18 0/20 Not estimable
Total (95% CI) 56 58 100.0 % 0.32 [ 0.02, 4.81 ]
Total events: 6 (Treatment), 14 (Control)
Heterogeneity: Tau2 = 2.95; Chi2 = 3.66, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.83 (P = 0.41)
0.002 0.1 1 10 500
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Analysis 3.3. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled
trials), Outcome 3 Catheter removal.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials)
Outcome: 3 Catheter removal








1 Gentamicin (IV) versus no treatment (preoperative)
Bennet-Jones 1988 0/13 1/14 0.36 [ 0.02, 8.06 ]
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Analysis 3.4. Comparison 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled
trials), Outcome 4 Death.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 3 Peri-operative IV prophylaxis versus none (placebo/no treatment controlled trials)
Outcome: 4 Death








Lye 1992 1/25 1/25 1.00 [ 0.07, 15.12 ]
0.05 0.2 1 5 20
Favours treatment Favours control
Analysis 5.1. Comparison 5 Topical disinfectants versus none, Outcome 1 Mortality (all cause).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 5 Topical disinfectants versus none
Outcome: 1 Mortality (all cause)








Waite 1997 5/61 4/56 43.2 % 1.15 [ 0.32, 4.06 ]
Wilson 1997 7/77 5/72 56.8 % 1.31 [ 0.44, 3.94 ]
Total (95% CI) 138 128 100.0 % 1.24 [ 0.54, 2.84 ]
Total events: 12 (Treatment), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 5.2. Comparison 5 Topical disinfectants versus none, Outcome 2 Exit site and tunnel infection
(number of patients with exit site and tunnel infection).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 5 Topical disinfectants versus none
Outcome: 2 Exit site and tunnel infection (number of patients with exit site and tunnel infection)








Luzar 1990 17/74 16/41 44.5 % 0.59 [ 0.33, 1.04 ]
Waite 1997 9/61 11/56 22.1 % 0.75 [ 0.34, 1.68 ]
Wilson 1997 14/77 15/72 33.4 % 0.87 [ 0.45, 1.68 ]
Total (95% CI) 212 169 100.0 % 0.71 [ 0.49, 1.03 ]
Total events: 40 (Treatment), 42 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
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Analysis 5.3. Comparison 5 Topical disinfectants versus none, Outcome 3 Peritonitis (number of patients
with peritonitis).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 5 Topical disinfectants versus none
Outcome: 3 Peritonitis (number of patients with peritonitis)








Luzar 1990 17/74 14/42 53.5 % 0.69 [ 0.38, 1.25 ]
Waite 1997 1/61 3/56 3.8 % 0.31 [ 0.03, 2.86 ]
Wilson 1997 13/77 15/72 42.6 % 0.81 [ 0.41, 1.58 ]
Total (95% CI) 212 170 100.0 % 0.72 [ 0.46, 1.11 ]
Total events: 31 (Treatment), 32 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 5.4. Comparison 5 Topical disinfectants versus none, Outcome 4 Catheter removal or replacement.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 5 Topical disinfectants versus none
Outcome: 4 Catheter removal or replacement








Waite 1997 5/61 5/56 40.7 % 0.92 [ 0.28, 3.00 ]
Wilson 1997 6/77 9/72 59.3 % 0.62 [ 0.23, 1.66 ]
Total (95% CI) 138 128 100.0 % 0.73 [ 0.34, 1.55 ]
Total events: 11 (Treatment), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 5.5. Comparison 5 Topical disinfectants versus none, Outcome 5 Technique failure.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 5 Topical disinfectants versus none
Outcome: 5 Technique failure








Wilson 1997 0/77 2/72 0.19 [ 0.01, 3.83 ]
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Analysis 5.6. Comparison 5 Topical disinfectants versus none, Outcome 6 Pruritus (local).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 5 Topical disinfectants versus none
Outcome: 6 Pruritus (local)








Wilson 1997 5/77 0/72 10.29 [ 0.58, 182.92 ]
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Analysis 6.1. Comparison 6 Germicidal chamber versus none, Outcome 1 Peritonitis rate
(episodes/patient-month versus total patient-months).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 6 Germicidal chamber versus none
Outcome: 1 Peritonitis rate (episodes/patient-month versus total patient-months)








Nolph 1985 44/601 53/753 1.04 [ 0.71, 1.53 ]
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Analysis 6.2. Comparison 6 Germicidal chamber versus none, Outcome 2 Mortality (all cause).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 6 Germicidal chamber versus none
Outcome: 2 Mortality (all cause)








Nolph 1985 4/74 11/93 0.46 [ 0.15, 1.38 ]
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Analysis 7.1. Comparison 7 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 1 Peritonitis
rate (episodes/patient-month versus total patient-months).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 7 Antistaphylococcal vaccine (Staphypan) versus placebo
Outcome: 1 Peritonitis rate (episodes/patient-month versus total patient-months)








Poole-Warren 1991 37/552 41/547 0.89 [ 0.58, 1.37 ]
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Analysis 7.2. Comparison 7 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 2 Exit site
and tunnel infection rate (episodes/patient-month versus total patient-months).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 7 Antistaphylococcal vaccine (Staphypan) versus placebo
Outcome: 2 Exit site and tunnel infection rate (episodes/patient-month versus total patient-months)








Poole-Warren 1991 52/565 49/542 1.02 [ 0.70, 1.48 ]
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Analysis 8.1. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 1 Mortality (all cause).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 1 Mortality (all cause)








1 Fusidate versus ofloxacin
Sesso 1994 0/9 1/9 39.8 % 0.33 [ 0.02, 7.24 ]
Subtotal (95% CI) 9 9 39.8 % 0.33 [ 0.02, 7.24 ]
Total events: 0 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 Mupirocin versus rifampin
Bernardini 1996 4/41 1/41 60.2 % 4.00 [ 0.47, 34.28 ]
Subtotal (95% CI) 41 41 60.2 % 4.00 [ 0.47, 34.28 ]
Total events: 4 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 50 50 100.0 % 1.49 [ 0.14, 16.15 ]
Total events: 4 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 1.25; Chi2 = 1.68, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 8.2. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 2 Exit site and tunnel
infection (number of patients with exit site and tunnel infection).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 2 Exit site and tunnel infection (number of patients with exit site and tunnel infection)








1 Fusidate versus ofloxacin
Sesso 1994 5/9 2/9 23.2 % 2.50 [ 0.65, 9.69 ]
Subtotal (95% CI) 9 9 23.2 % 2.50 [ 0.65, 9.69 ]
Total events: 5 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 Vancomicin versus cefazolin (preoperative)
Gadallah 2000 3/103 6/102 23.1 % 0.50 [ 0.13, 1.93 ]
Subtotal (95% CI) 103 102 23.1 % 0.50 [ 0.13, 1.93 ]
Total events: 3 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
3 Mupirocin versus rifampin
Bernardini 1996 11/41 13/41 53.8 % 0.85 [ 0.43, 1.66 ]
Subtotal (95% CI) 41 41 53.8 % 0.85 [ 0.43, 1.66 ]
Total events: 11 (Treatment), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 153 152 100.0 % 0.96 [ 0.45, 2.03 ]
Total events: 19 (Treatment), 21 (Control)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.96, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 8.3. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 3 Peritonitis (number of
patients with peritonitis).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 3 Peritonitis (number of patients with peritonitis)








1 Vancomicin versus cefazolin (preoperative)
Gadallah 2000 1/103 9/102 42.9 % 0.11 [ 0.01, 0.85 ]
Subtotal (95% CI) 103 102 42.9 % 0.11 [ 0.01, 0.85 ]
Total events: 1 (Treatment), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
2 Mupirocin versus rifampin
Bernardini 1996 15/41 12/41 57.1 % 1.25 [ 0.67, 2.33 ]
Subtotal (95% CI) 41 41 57.1 % 1.25 [ 0.67, 2.33 ]
Total events: 15 (Treatment), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 144 143 100.0 % 0.44 [ 0.03, 5.73 ]
Total events: 16 (Treatment), 21 (Control)
Heterogeneity: Tau2 = 2.90; Chi2 = 5.87, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 8.4. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 4 Peritonitis rate
(episodes/patient-month versus total patient-months).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 4 Peritonitis rate (episodes/patient-month versus total patient-months)








1 Fusidate versus ofloxacin
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Mupirocin versus neomicin sulphate
Perez 1992 5/133 4/76 16.9 % 0.71 [ 0.20, 2.58 ]
Subtotal (95% CI) 133 76 16.9 % 0.71 [ 0.20, 2.58 ]
Total events: 5 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 Mupirocin versus rifampin
Bernardini 1996 22/538 22/488 83.1 % 0.91 [ 0.51, 1.62 ]
Subtotal (95% CI) 538 488 83.1 % 0.91 [ 0.51, 1.62 ]
Total events: 22 (Treatment), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 671 564 100.0 % 0.87 [ 0.51, 1.48 ]
Total events: 27 (Treatment), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
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Analysis 8.5. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 5 Exit site and tunnel
infection (rate).
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 5 Exit site and tunnel infection (rate)








1 Fusidate versus ofloxacin
Sesso 1994 6/74 2/73 37.1 % 2.96 [ 0.62, 14.19 ]
Subtotal (95% CI) 74 73 37.1 % 2.96 [ 0.62, 14.19 ]
Total events: 6 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
2 Mupirocin versus rifampin
Bernardini 1996 19/538 25/488 62.9 % 0.69 [ 0.38, 1.24 ]
Subtotal (95% CI) 538 488 62.9 % 0.69 [ 0.38, 1.24 ]
Total events: 19 (Treatment), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 612 561 100.0 % 1.18 [ 0.30, 4.72 ]
Total events: 25 (Treatment), 27 (Control)
Heterogeneity: Tau2 = 0.70; Chi2 = 2.93, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 8.6. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 6 Nausea.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 6 Nausea








1 Mupirocin versus rifampin
Bernardini 1996 0/41 4/41 0.11 [ 0.01, 2.00 ]
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Analysis 8.7. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 7 Catheter removal or
replacement.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 7 Catheter removal or replacement








1 Fusidate versus ofloxacin
Sesso 1994 4/9 3/9 52.6 % 1.33 [ 0.41, 4.33 ]
Subtotal (95% CI) 9 9 52.6 % 1.33 [ 0.41, 4.33 ]
Total events: 4 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 Mupirocin versus rifampin
Bernardini 1996 4/41 5/41 47.4 % 0.80 [ 0.23, 2.77 ]
Subtotal (95% CI) 41 41 47.4 % 0.80 [ 0.23, 2.77 ]
Total events: 4 (Treatment), 5 (Control)
Heterogeneity: not applicable
0.2 0.5 1 2 5
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(Continued . . . )
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(. . . Continued)








Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 50 50 100.0 % 1.05 [ 0.45, 2.46 ]
Total events: 8 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 8.8. Comparison 8 Antibiotic prophylaxis head-to-head agents, Outcome 8 Nasal irritation.
Review: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
Comparison: 8 Antibiotic prophylaxis head-to-head agents
Outcome: 8 Nasal irritation








1 Fusidate versus ofloxacin
Sesso 1994 1/9 0/9 3.00 [ 0.14, 65.16 ]
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A D D I T I O N A L T A B L E S
Table 1. Guidelines on antimicrobial interventions to prevent peritonitis in PD
Guideline Country Year Recommendation
K-DOQI United States of America NA No guideline
British Renal Association United Kingdom NA No guideline
Canadian Society of Nephrol-
ogy
Canada NA No guideline
European Best Practice Guide-
lines




NA 2000 • Prophylactic antibiotic therapy for S. aureus nasal
carriage recommended to decrease the risk of S. aureus
catheter exit site/tunnel infections
• Topical disinfectants or antibacterial soaps and topical
exit-site mupirocin ointment recommended to decrease the
risk of exit site/tunnel infections
• Preoperative prophylaxis with first generation
cephalosporin recommended at time of catheter insertion;
routine use of vancomycin should be avoided
• Prophylactic antibiotic therapy for S. aureus nasal
carriage recommended to decrease the risk of S. aureus
catheter exit site/tunnel infections
• Topical disinfectants or antibacterial soaps and topical
exit-site mupirocin ointment recommended to decrease the
risk of exit site/tunnel infections
• Preoperative prophylaxis with first generation
cephalosporin recommended at time of catheter insertion;
routine use of vancomycin should be avoided
• Prophylactic antibiotic therapy for S. aureus nasal
carriage recommended to decrease the risk of S. aureus
catheter exit site/tunnel infection
• Topical disinfectants or antibacterial soaps and topical
exit-site mupirocin ointment recommended to decrease the
risk of exit site/tunnel infections
• Pre-operative prophylaxis with first generation
cephalosporin recommended at time of catheter insertion;
routine use of vancomycin should be avoided
CARI guidelines
CARI 2003
Australia 2003 • Prophylactic therapy with mupirocin ointment,
especially for S. aureus carriage (intranasally or at exit site)
recommended to decrease the risk of S. aureus catheter exit
site/tunnel infections and peritonitis
• Antibiotic prophylaxis with a first generation
cephalosporin at the time of catheter insertion recommended
to decrease the incidence of peritonitis- Prophylactic therapy
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Table 1. Guidelines on antimicrobial interventions to prevent peritonitis in PD (Continued)
with mupirocin ointment, especially for S. aureus carriage
(intranasally or at exit site) recommended to decrease the risk
of S. aureus catheter exit site/tunnel infections and peritonitis
• Antibiotic prophylaxis with a first generation
cephalosporin at the time of catheter insertion recommended
to decrease the incidence of peritonitis
• Prophylactic therapy with mupirocin ointment,
especially for S. aureus carriage (intranasally or at exit site)
recommended to decrease the risk of S. aureus catheter exit
site/tunnel infections and peritonitis
• Antibiotic prophylaxis with a first generation
cephalosporin at the time of catheter insertion recommended
to decrease the incidence of peritonitis
Table 2. Electronic search strategies
Database searched Search terms
CENTRAL #1 peritoneal next dialysis
#2 PERITONEAL DIALYSIS (MeSH explode))
#3 pd or capd or ccpd
#4 #1 or #2 or #3
#5 PERITONITIS (MeSH)
#6 periton*
#7 #5 or #6
#8 #4 and #7
MEDLINE (1966 to most recent) 1 exp Peritoneal Dialysis/
2 peritoneal dialysis.tw.











14 (plac$ or insert$).tw.
15 (break-in or immobil$).tw.
16 surg$.tw.
17 or/13-16
18 12 and 17
19 and/4,11,13
20 18 or 19
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Table 3. Results of head-to-head trials of antimicrobial agents to prevent peritonitis
Outcome analyzed Number of studies Number of patients RR (95% CI)
Sodium fusidate (2%) nasal ointment versus ofloxacin
All-cause mortality 1 18 0.33 (0.02 to 7.24)
Exit-site/tunnel
infection
1 18 2.50 (0.65 to 9.69)
Exit-site/tunnel
infection rate
1 147 (patient months) 2.96 (0.62 to 14.19)
Catheter removal or re-
placement
1 18 1.33 (0.41 to 4.33)
Nasal irritation 1 18 3.00 (0.14 to 65.16)
Nasal mupirocin versus neomicin sulphate
Peritonitis rate 1 209 (patient months 0.71 (0.20 to 2.58)
Nasal mupirocin versus oral rifampin
Nausea 1 82 0.11 (0.01 to 2.00)
Perioperative vancomicin versus cefazolin
Peritonitis 1 205 0.11 (0.01 to 0.85)
Table 4. Other outcomes analyzed
Outcome analyzed Number of studies Number of patients RR (95% CI)
Oral antibiotic prophylaxis
Pruritus 1 64 3.00 (0.13 to 71.00)
Diarrhoea 1 64 0.09 (0.01 to 1.58)
Nausea 1 64 9.00 (0.50 to 160.59)
Allergy 1 64 5.00 (0.25 to 100.20)
Nasal antibiotic prophylaxis
Nasal irritation 1 15 2.10 (0.10 to 44.40)
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Table 4. Other outcomes analyzed (Continued)
Rhinitis 1 267 0.74 (0.27 to 2.09)
Headache 1 267 0.99 (0.14 to 6.94)
Diarrhoea 1 267 1.65 (0.40 to 6.78)
Nausea 1 267 0.99 (0.14 to 6.94)
Vomiting 1 267 2.98 (0.61 to 14.94)
Pruritus 1 267 1.49 (0.25 to 8.77)
Topical disinfectants
Technique failure 1 149 0.19 (0.01 to 3.83)
Pruritus 1 149 10.29 (0.58 to 182.92)
WH A T ’ S N E W
Last assessed as up-to-date: 17 December 2007.
Date Event Description
18 March 2010 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 4, 2004
Date Event Description
13 May 2009 Amended Contact details updated.
16 September 2008 Amended Converted to new review format.
18 December 2007 Amended New trials sought but none found
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